News & Publications

News & Publications

Press Releases

  • Arvinas Appoints Dr. John Houston as President and Chief Executive Officer

    September 20, 2017

    NEW HAVEN, Conn., September 20, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of John Houston, Ph.D., as president and chief executive officer. Dr. Houston will also join the board of directors of Arvinas Holding Company, LLC, and all of its ...

    Read More
  • Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium

    February 17, 2017

    NEW HAVEN, Conn., February 17, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the presentation of new preclinical data on its oral androgen receptor (AR) PROTAC during a poster session at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium (ASCO GU) ...

    Read More
  • Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer

    January 5, 2017

    NEW HAVEN, Conn., January 5, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has appointed Dr. John Houston as President of Research and Development and Chief Scientific Officer to lead discovery research, translational research and early clinical development.  Dr. Houston was ...

    Read More
  • Arvinas Presents Data on Oral Estrogen Receptor PROTAC Degrader at 2016 San Antonio Breast Cancer Symposium

    December 9, 2016

    NEW HAVEN, Conn., December 9, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs, which function via targeted protein degradation, today announced that data were presented during an oral presentation at the 2016 San Antonio Breast Cancer Symposium highlighting the potential of its oral estrogen receptor alpha ...

    Read More
  • Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting

    December 6, 2016

    NEW HAVEN, Conn., December 6, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation, today announced that preclinical data were presented by three Arvinas collaborators at the 2016 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The data ...

    Read More
  • Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium

    November 29, 2016

    NEW HAVEN, Conn., November 29, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that data were presented by Dr. Kevin Coleman, Vice President of Exploratory Biology, during an oral presentation at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium being held November ...

    Read More
  • Arvinas Publishes First Peer-Reviewed, In Vivo Data from its Proprietary PROTAC Technology

    June 7, 2016

    NEW HAVEN, Conn., June 7, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the publication of a peer-reviewed joint Arvinas-Yale University paper focusing on the development of degraders of bromodomain and extraterminal domain (BET) proteins for the treatment of castration-resistant prostate cancer (CRPC).  ...

    Read More
  • Arvinas to Present Data at the 2016 AACR Annual Meeting

    April 14, 2016

    NEW HAVEN, Conn., April 14, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present two posters at the 2016 Annual Meeting of the American Association for Cancer Research (“AACR”) in New Orleans, Louisiana, being held from April 16th to the ...

    Read More
  • Arvinas Appoints Angela Shen as Chief Medical Officer

    March 2, 2016

    NEW HAVEN, CT, March 2, 2016 – Arvinas LLC, a biotechnology company creating a new class of oncology drugs based on protein degradation, announced the appointment of Angela Shen, M.D., M.B.A, as chief medical officer of the company. Dr. Shen brings extensive experience in clinical development, medical affairs, and business development to Arvinas, having led ...

    Read More
  • Arvinas Presents Data at the 2015 ASH Annual Meeting

    December 3, 2015

    NEW HAVEN, Conn., December 3, 2015 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has three presentations, two oral and one poster, at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 5-8, 2015. All presentations focus on ...

    Read More
  • Arvinas Secures $41.6M Series B Financing – Appoints New Board Members

    October 21, 2015

    New Haven, CT – October 21, 2015 – Arvinas LLC (“Arvinas”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has closed a Series B financing round of $41.6 million. All of the initial Series A investors, including the two lead Series A investors, Canaan Partners ...

    Read More
  • Arvinas Inks Strategic License Agreement with Genentech

    October 1, 2015

    New Haven, CT, October 1, 2015 – Arvinas, Inc. (a wholly owned subsidiary of Arvinas, LLC), a private biotechnology company creating a new class of drugs based on targeted protein degradation, entered into a license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics using Arvinas’ novel PROTAC technology. ...

    Read More
  • FierceBiotech names Arvinas as one of its “Fierce 15” Biotech Companies of 2015

    September 30, 2015

    New Haven, CT – September 30, 2015 – Arvinas LLC (“Arvinas”) today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Arvinas is harnessing the body’s own natural quality control system to target and degrade pathogenic proteins ...

    Read More
  • Arvinas Appoints Robert Kleinfield as Chief Development Officer

    September 23, 2015

    NEW HAVEN, CT, September 23, 2015 – Arvinas LLC, a biotechnology company creating a new class of oncology drugs based on protein degradation, announced the appointment of Robert Kleinfield, Ph.D., as chief development officer of the company. Dr. Kleinfield brings over 20 years of product development and project leadership experience to Arvinas, having led programs in ...

    Read More
  • Arvinas Publishes First Peer-Reviewed Paper on its Proprietary PROTAC Technology

    June 4, 2015

    NEW HAVEN, Conn., June 4, 2015 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announces the publication of a joint Arvinas-Yale University paper focusing on the development of degraders of BRD4, a protein implicated in both solid tumors and hematologic cancers. The paper, entitled “Hijacking the ...

    Read More
  • Arvinas Announces Strategic R&D Collaboration with Merck to Study Novel Protein Degradation Technology

    April 7, 2015

    NEW HAVEN, Conn., April 7, 2015 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, announced a strategic collaboration with Merck, known as MSD outside of the United States and Canada, in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal ...

    Read More
  • Arvinas Appoints Manuel Litchman as President and Chief Executive Officer

    January 12, 2015

    January 12, 2015 – New Haven, CT – Arvinas Inc., a biotechnology company creating a new class of oncology drugs based on protein degradation, today announced that it has appointed Manuel Litchman, M.D., as President and Chief Executive Officer of the company. Dr. Litchman was most recently Senior Vice President and Global Program Head at ...

    Read More
  • Dr. Craig Crews Honored as CURE Entrepreneur of the Year

    December 17, 2014

    At a ceremony December 3, Arvinas founder and Chief Scientific Advisor Dr. Craig M. Crews was presented the first annual CURE Entrepreneur of the Year Award, sponsored by the law firm of Shipman & Goodwin LLP, Counselors at Law. The award recognizes Dr. Crews’ longstanding commitment to entrepreneurship and the translation of fundamental basic research to new ...

    Read More
  • Nature Biotechnology Names Arvinas a Top Spinout in 2013

    March 21, 2014

    Nature Biotechnology editors have chosen Arvinas, Inc. as one of the ten best-funded startups pursuing groundbreaking science. Firms were identified first on the basis of the amount of the series-A funding they raised (a measure of commercial excitement) and second on our editors’ assessment of their research. Read the feature article Nature Biotechnology’s academic spinouts of 2013.

    Read More
  • Arvinas Appoints Jim Winkler as Chief Scientific Officer

    February 11, 2014

    New Haven, Conn. – February 11, 2014 – Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of Jim Winkler, Ph.D., to the position of Chief Scientific Officer. Dr. Winkler will be responsible for the discovery and development of potential drug compounds that will target ...

    Read More
  • Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation

    September 26, 2013

    New Haven, CT–September 26, 2013—Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form equity, from the Connecticut Department of Economic and Community Development and ...

    Read More